Last reviewed: June 29, 2026
Last updated: June 29, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, the active ingredient in Wegovy, works by activating glucagon-like peptide-1 receptors in the brain and digestive system. The FDA-approved starting dose is 0.25 mg injected once weekly, with increases every four weeks until reaching a maintenance dose. This gradual approach—called dose titration—allows your body to adapt and minimizes nausea and gastrointestinal side effects that often occur with higher starting doses.
Understanding Semaglutide's Starting Dose in Wegovy
The 0.25 mg starting dose of semaglutide represents a gentle introduction to GLP-1 receptor activation. This low initial amount triggers appetite-suppressing signals without overwhelming your system, which is why most patients tolerate it well. Clinical trials show that starting low and titrating up leads to better long-term adherence compared to higher initial doses.
Your doctor determines whether the 0.25 mg dose is right for you based on your medical history, kidney function, and any prior GLP-1 exposure. Some patients with previous experience may start slightly higher, but the standard protocol remains conservative. This patient-centered approach reflects decades of endocrinology research showing that gradual dose escalation produces sustained weight loss with fewer discontinuations due to side effects.
How Semaglutide's Dose Escalation Schedule Works
Wegovy follows a 16-week titration schedule that increases from 0.25 mg to a typical maintenance of 2.4 mg. Week 1–4 uses 0.25 mg, week 5–8 advances to 0.5 mg, week 9–12 moves to 1 mg, and week 13–16 reaches 1.7 mg. Patients who need additional weight loss can continue to 2.4 mg in the final titration phase. This structured progression gives your GLP-1 receptors time to upregulate—a biological process where more receptors become available for activation.
The four-week intervals between dose increases allow your body to establish a new equilibrium at each level. Many patients notice their appetite suppression and energy expenditure shift within 7–10 days of each increase. If side effects become troublesome, your provider can pause at a lower maintenance dose, since clinical evidence shows meaningful weight loss occurs even at 1 mg or 1.7 mg weekly.
Why Semaglutide Works: Mechanism Beyond Appetite Suppression
Semaglutide reduces hunger by mimicking glucagon-like peptide-1, a hormone your gut naturally produces when you eat. It slows gastric emptying—the rate at which food moves from your stomach into your small intestine—which prolongs satiety signals to your brain. This means you feel fuller longer after meals and experience fewer cravings between eating occasions. The drug also increases insulin secretion when blood sugar rises, improving glucose control in people with prediabetes or type 2 diabetes.
Beyond appetite control, semaglutide influences energy expenditure and fat metabolism at the cellular level. Research shows it activates brown adipose tissue, which burns calories to produce heat, and reduces inflammation in fat cells. These metabolic changes persist because they reshape the biological pathways that control your weight set point—the weight your body naturally gravitates toward. This explains why many patients maintain weight loss even after pausing treatment, unlike older weight loss drugs that only suppressed appetite.
PlexusDx Compounded Semaglutide vs. Branded Wegovy
PlexusDx offers compounded semaglutide injections from licensed 503A compounding pharmacies at a flat $149 per month starting rate, with no flat per-compound pricing increases. The medication contains the identical semaglutide molecule as branded Wegovy but costs significantly less because compounding eliminates brand markup and packaging expenses. Your dose may need to go up; your price won't—a pricing model designed to remove financial barriers to optimal weight loss therapy.
Compounded semaglutide undergoes the same quality standards as FDA-approved medications, with independent testing for sterility, potency, and purity. PlexusDx serves all 50 states without insurance requirements, membership fees, or prior authorization delays. Injections are HSA/FSA eligible, and patients can add the Precision Peptide Genetic Test ($99) after their first month to identify personalized peptide-pathway variants that predict semaglutide responsiveness.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the actual starting dose of semaglutide in Wegovy?
Wegovy's starting dose is 0.25 mg injected subcutaneously once weekly. This low dose minimizes nausea and allows your GLP-1 receptors to adapt safely. Most patients increase to the next dose level every four weeks until reaching their target maintenance dose, typically 1.7 mg to 2.4 mg weekly.
How long does it take to see weight loss results from semaglutide?
Most patients notice appetite suppression within 3–7 days of their first injection. Measurable weight loss typically appears within 2–4 weeks, with accelerating results over 8–12 weeks as doses increase. Clinical trials show an average 15% body weight reduction over 68 weeks with consistent dosing and lifestyle support.
Can I start semaglutide at a higher dose to lose weight faster?
Starting at a dose higher than 0.25 mg significantly increases the risk of severe nausea, vomiting, and gastrointestinal distress, leading many patients to discontinue treatment. Gradual titration produces better long-term results and adherence. Your healthcare provider will never recommend starting above 0.25 mg unless you have prior GLP-1 experience.
How much does PlexusDx compounded semaglutide cost compared to Wegovy?
PlexusDx compounded semaglutide injections start at $149 per month with no additional charges as your dose increases. Branded Wegovy typically costs $900–$1,400 monthly without insurance. Patients save 70–85% with PlexusDx while receiving the same active ingredient from licensed 503A compounding pharmacies.
What genetic factors influence how well semaglutide works for me?
PlexusDx's Precision Peptide Genetic Test identifies variants in GLP1R, GIPR, FTO, and MC4R genes that predict your individual semaglutide response. The GLP1R rs6923761 variant, for example, influences how many GLP-1 receptors your cells express, directly affecting medication efficacy. Testing costs $99 after your first month of treatment.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Your Journey: Can You Take Wegovy One Day Late and What It Means for Your Progress
Is Wegovy Stronger Than Ozempic?